期刊文献+

Targeted therapies in epithelial ovarian cancer: Molecular mechanisms of action 被引量:14

Targeted therapies in epithelial ovarian cancer: Molecular mechanisms of action
下载PDF
导出
摘要 Ovarian cancer is the leading cause of death in women with gynecological cancer. Most patients are diagnosed at an advanced stage and have a poor prognosis.Currently, surgical tumor debulking, followed by platinum- and taxane-based chemotherapy is the standard treatment for advanced ovarian cancer. However, these patients are at great risk of recurrence and emerging drug resistance. Therefore, novel treatment strategies are required to improve outcomes for women with advanced ovarian cancer. A variety of molecular targeted agents, the majority of which are monoclonal antibodies and small-molecule protein-kinase inhibitors, have been explored in the management of ovarian cancer. The targets of these agents include angiogenesis, the human epidermal growth factor receptor family, ubiquitinproteasome pathway, epigenetic modulators, poly(ADPribose) polymerase (PARP), and mammalian target of rapamycin (mTOR) signaling pathway, which are aberrant in tumor tissue. The antiangiogenic agent, bevacizumab, has been reported as the most effective targeted agent and should be included in the standard chemotherapeutic regimen for advanced ovarian cancer. PARP inhibitors, which are mainly used in breast and ovarian cancer susceptibility gene-mutated patients, and mTOR inhibitors are also attractive treatment strategies, either alone or combination with chemotherapy, for ovarian cancer. Understanding the tumor molecular biology and identification of predictive biomarkers are essential steps for selection of the best treatment strategies. This article reviews the molecular mechanisms of the most promising targeted agents that are under early phase clinical evaluation for ovarian cancer. Ovarian cancer is the leading cause of death in women with gynecological cancer. Most patients are diagnosed at an advanced stage and have a poor prognosis. Currently, surgical tumor debulking, followed by platinum- and taxane-based chemotherapy is the standard treatment for advanced ovarian cancer. However, these patients are at great risk of recurrence and emerging drug resistance. Therefore, novel treatment strategies are required to improve outcomes for women with advanced ovarian cancer. A variety of molecular targeted agents, the majority of which are monoclonal antibodies and small-molecule protein-kinase inhibitors, have been explored in the management of ovarian cancer. The targets of these agents include angiogenesis, the human epidermal growth factor receptor family, ubiquitin-proteasome pathway, epigenetic modulators, poly(ADP-ribose) polymerase (PARP), and mammalian target of rapamycin (mTOR) signaling pathway, which are aberrant in tumor tissue. The antiangiogenic agent, bevacizumab, has been reported as the most effective targeted agent and should be included in the standard chemotherapeutic regimen for advanced ovarian cancer. PARP inhibitors, which are mainly used in breast and ovarian cancer susceptibility gene-mutated patients, and mTOR inhibitors are also attractive treatment strategies, either alone or combination with chemotherapy, for ovarian cancer. Understanding the tumor molecular biology and identification of predictive biomarkers are essential steps for selection of the best treatment strategies. This article reviews the molecular mechanisms of the most promising targeted agents that are under early phase clinical evaluation for ovarian cancer.
出处 《World Journal of Biological Chemistry》 CAS 2010年第7期209-220,共12页 世界生物化学杂志(英文版)(电子版)
关键词 TARGETED therapy EPITHELIAL OVARIAN cancer Molecular target MONOCLONAL ANTIBODY SMALL-MOLECULE inhibitor Targeted therapy Epithelial ovarian cancer Molecular target Monoclonal antibody Small-molecule inhibitor
  • 相关文献

参考文献11

  • 1Spannuth WA,Nick AM,Jennings NB,Armaiz-Pena GN,Mangala LS,Danes CG,Lin YG,Merritt WM,Thaker PH,Ka- mat AA,Han LY,Tonra JR,Coleman RL,Ellis LM,Sood AK.Functional significance of VEGFR-2 on ovarian cancer cells. International Journal of Cancer . 2009
  • 2Orlowski RZ,Kuhn DJ.Proteasome inhibitors in cancer therapy:lessons from the first decade. Clinical Cancer Research . 2008
  • 3Jones PA,Baylin SB.The epigenomics of cancer. Cell . 2007
  • 4Esteller M.Epigenetics in cancer,2008(11).
  • 5F. Ciardiello,G. Tortora.EGFR antagonists in cancer treatment. The New England Journal of Medicine . 2008
  • 6Folkman J.Tumor angiogenesis: therapeutic implication. New England Journal of Homeopathy . 1971
  • 7Hanahan D,Folkman J.Patterns and emerging mechanisms of the angiogenic switchduring tumorigenesis. Cell . 1996
  • 8Hicklin DJ,Ellis LM.Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. Journal of Clinical Oncology . 2005
  • 9Ferrara N;Davis-Smyth T.The biology of vascular endothelial growth factor,1997.
  • 10Druker BJ;Tamura S;Buchdunger E.Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells,1996.

共引文献12

同被引文献64

引证文献14

二级引证文献80

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部